Circular Genomics

SAN DIEGO, March 17, 2025 /PRNewswire/ — Circular Genomics, a global leader in circular RNA (circRNA) biomarkers for precision neurology and psychiatry, today announced it is moving the company’s headquarters to Lilly Gateway Labs in San Diego, California, which is operated in partnership with Alexandria Real Estate Equities, Inc., to advance the development of Alzheimer’s disease […]

ALBUQUERQUE, N.M., Sept. 16, 2024 /PRNewswire/ — Circular Genomics, the global leader in circular RNA biomarkers for precision psychiatry and neurology, today announced the launch of MindLight, the first circular RNA biomarker-based assay designed to predict whether a patient with depression, also known as major depressive disorder, will respond to selective serotonin reuptake inhibitor (SSRI)

ALBUQUERQUE, N.M., March 18, 2024 /PRNewswire/ — Circular Genomics, the global leader in circular RNA biomarkers for precision psychiatry and neurology, today announced the addition of Michael F. Ackermann, PhD, MBA to its Scientific Advisory Board (SAB). Dr. Ackermann brings significant expertise in biopharmaceutical industry including antidepressant drug development to Circular Genomics. Circular Genomics is at

ALBUQUERQUE, N.M., Jan. 24, 2024 /PRNewswire/ — Circular Genomics, the global leader in advancing circular RNA biomarkers for precision psychiatry and neurology, today announced the closing of an $8.3 Million Series A investment round. Led by Mountain Group Partners, this round also welcomes new investor UNM Rainforest Innovations in addition to initial investors, including Cottonwood Technology

Albuquerque, NM, July 11, 2023 (GLOBE NEWSWIRE) — Circular Genomics, the global leader in the use of circular RNA (circRNA) biomarkers for precision psychiatry, today announced the results of a new study that shows circRNAs can be used to predict with high accuracy a patient’s response to the SSRI, Sertraline, one of the most common

ALBUQUERQUE, N.M., April 27, 2023 /PRNewswire/ — Circular Genomics, the leading company in developing circular RNA-based precision medicine tools, data and diagnostics for neurology and psychiatry, has appointed Paul Sargeant, PhD, to serve as Chief Executive Officer. The company is leveraging exclusive licenses and technologies in the use of circular RNA in major depressive disorder

Devin Coldewey@techcrunch / 12:40 PM MDT•October 18, 2022   Image Credits: Bryce Durbin / TechCrunch For many people who live with depression, medication is an important part of managing the condition. But knowing which will work for you can be a difficult months-long process. Circular Genomics claims its new form of genetic testing can identify

Neesha A. Tambe@neeshatambe / 9:00 AM MDT•October 18, 2022   Image Credits: TechCrunch Watch Session Recordings With An Online Pass – Book Today We’re positively thrilled that Startup Battlefield is live and in person at TechCrunch Disrupt 2022. In a new era of the legendary startup competition, TechCrunch editorial hand-selected 200 startups, out of thousands

December 14, 2021 December 14, 2021 – Circular Genomics, an Albuquerque, New Mexico-based circRNA company, is pleased to announce the closing of their $4.5M Series Seed investment round. The round was co-led by Cottonwood Technology Fund III and Tramway Venture Partners along with Mountain Group Partners. Other participants in the round include several individual investors.